PegBio Co Ltd is a China-based company primarily engaged in the discovery and development of innovative therapies. The Company's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The Company's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia). *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares)
279,164,339 (as at 30 Jun 2025)
Industry
Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Industry Classification (CSIC) is provided by China Securities Indexes Co., Ltd. and only available for companies dually listed in Hong Kong and Shanghai. Please see the . (CSIC)
Listing Date
27 May 2025
Financial Year Ends
-
Chairman
Michael Min Xu
Principal Office
Room 606, Building 1
Haozhang Tower
Gongshu District, Hangzhou
Zhejiang Province, PRC
Place of Incorporation
PRC
Listing Category
Primary Listing
Primary Market
Depositary
DR Ratio
Description
Amount Outstanding
-
-
Subscription Rights per Unit
Subscription price/Strike price
Listing Date
The entitlement ratio in general represents the number of warrants required to be exercised into one share or one unit of the underlying asset (subject to any adjustments as may be necessary to reflect any capitalization, rights issue, distribution or the like).Entitlement Ratio
Subscription Period
Underlying Stock Code
Trading Currency